Organization & Developments: GSK (GlaxoSmithKline)_Archive 2011-2014

Parents

2011: 2nd UPDATE: FDA Approves Lupus Drug From Human Genome, Glaxo (2011)
2011: Alnylam and Glaxo Partner on RNAi for Vaccine Production (2011)
2011: Experimental drug for Type 1 diabetes failed to meet the main clinical goal of a late-stage study, called Defend-1 (2011)
2011: GlaxoSmithKline taps Sproxil for SMS drug authentication (2011)
2011: PATH Partners With GSK on Malaria Vaccine (2011)
2012: antigenicsPhase 3 Clinical Trial of GSK’s Herpes Zoster Vaccine Candidate Containing Agenus’ QS-21 Commences in Immunocompromised Patients (2012)
2013: Albiglutide, diabetes drug key to Human Genome Sciences-GlaxoSmithKline merger, proves effective
2013: Are you developing an implantable bioelectronic device? GSK may have $1M for you_medcitynews (2013)
2013: Glaxo Setting Up San Diego Outpost to Oversee its Westward Expansion (2013)
2013: GlaxoSmithKline, Gates Foundation Launch $1.8 Million Vaccine Initiative (2013)
2014: In Pursuit of Hot Autoimmune Target, GSK and Academics Team Up
2014: NanoBio and GSK Announce Licensing Agreement